{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:55:27Z","timestamp":1784336127121,"version":"3.55.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels. Pulmonary involvement occurs in a subset of patients, though the overall prevalence of pulmonary lesions in scleromyxedema is unknown. Since pulmonary hypertension presumably occurs in these patients due to disease progression and development of additional conditions, treatment of the underlying plasma cell dyscrasia and connective tissue disorder may improve pulmonary hypertension symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An elderly patient with scleromyxedema developed pulmonary hypertension refractory to vasodilator and diuretic therapy and subsequently multiple myeloma that responded to a combination therapy of bortezomib, cyclophosphamide, and dexamethasone treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment of the underlying disease(s) that contributed to pulmonary hypertension development with anti-neoplastic agents like bortezomib may improve cardiopulmonary symptoms secondary to reducing abnormal blood cell counts and paraprotein levels.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-019-1020-6","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T15:02:57Z","timestamp":1578582177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5123-8823","authenticated-orcid":false,"given":"Mazen","family":"Kreidy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Hilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Yachoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/archderm.1964.01590270132030","volume":"89","author":"JT McCarthy","year":"1964","unstructured":"McCarthy JT, Osserman E, Lombardo PC, Takatsuki K. An abnormal serum globulin in lichen myxedematosus. Arch Dermatol. 1964;89:446\u201350.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1020_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00005792-198801000-00004","volume":"67","author":"SE Gabriel","year":"1988","unstructured":"Gabriel SE, Perry HO, Oleson GB, Bowles CA. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67(1):58\u201365.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1020_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","volume":"33","author":"AM Dinneen","year":"1995","unstructured":"Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33(1):37\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"1020_CR4","doi-asserted-by":"crossref","unstructured":"Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006;24(6):493\u20137.","DOI":"10.1016\/j.clindermatol.2006.07.011"},{"issue":"1","key":"1020_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MD.0b013e3181630835","volume":"87","author":"M Blum","year":"2008","unstructured":"Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87(1):10\u201320.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1020_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaad.2013.01.007","volume":"69","author":"F Rongioletti","year":"2013","unstructured":"Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1020_CR7","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaad.2015.12.021","volume":"74","author":"F Rongioletti","year":"2016","unstructured":"Rongioletti F, Merlo G, Carli C, Cribier B, Metze D, Calonje E, et al. Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. J Am Acad Dermatol. 2016;74(6):1194\u2013200.","journal-title":"J Am Acad Dermatol"},{"key":"1020_CR8","unstructured":"Rongioletti F. Scleromyxedema. Callen J, ed. UpToDate. Waltham: Wolters Kluwer. UpToDate Inc http:\/\/www.uptodate.com. Accessed on 22 Aug 2017."},{"issue":"3","key":"1020_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","volume":"53","author":"C Ferreli","year":"2017","unstructured":"Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):306\u201336.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"1020_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/jdv.14466","volume":"31","author":"R Knobler","year":"2017","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 2: Scleromyxedema, scleredema and nephrogenic s ystemic fibrosis. J Eur Acad Dermatol Venereol. 2017;31(9):1581\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.sder.2006.04.001","volume":"25","author":"F Rongioletti","year":"2006","unstructured":"Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg. 2006;25:100.","journal-title":"Semin Cutan Med Surg"},{"issue":"4","key":"1020_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000248432","volume":"178","author":"AS Alberts","year":"1989","unstructured":"Alberts AS, Schulz EJ, Falkson G, Simson IW, Coccia-Portugal MA. Normalization of skin appearance in a patient with scleromyxoedema after intensive chemotherapy for Hodgkin's disease. Dermatol. 1989;178(4):221\u20134.","journal-title":"Dermatol"},{"issue":"10","key":"1020_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1365-4362.1989.tb02439.x","volume":"28","author":"R Gim\u00e9nez Garcia","year":"1989","unstructured":"Gim\u00e9nez Garcia R, Garcia SG, Suarez Vilela D, Moro Sanchez MJ. Scleromyxedema associated with non-Hodgkin lymphoma. Int J Dermatol. 1989;28(10):670\u20131.","journal-title":"Int J Dermatol"},{"issue":"2 Pt 2","key":"1020_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0190-9622(98)70567-5","volume":"38","author":"A Godby","year":"1998","unstructured":"Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38(2 Pt 2):289\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1020_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1067\/mjd.2001.111903","volume":"45","author":"B Loggini","year":"2001","unstructured":"Loggini B, Pingitore R, Avvenente A, Giuliano G, Barachini P. Lichen myxedematosus with systemic involvement: clinical and autopsy findings. J Am Acad Dermatol. 2001;45(4):606\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1020_CR16","first-page":"852","volume":"20","author":"C De Simone","year":"2010","unstructured":"De Simone C, Castriota M, Carbone A, Marini Bettolo P, Pieroni M, Rongioletti F. Cardiomyopathy in scleromyxedema: Report of a fatal case. Eur J Dermatol. 2010;20(6):852\u20133.","journal-title":"Eur J Dermatol"},{"issue":"10","key":"1020_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ajh.22131","volume":"86","author":"NM Fett","year":"2011","unstructured":"Fett NM, Toporcer MB, Dalmau J, Shinohara MM, Vogl DT. Scleromyxedema and dermato\u2013neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol. 2011;86(10):893\u20136.","journal-title":"Am J Hematol"},{"issue":"5 suppl 1","key":"1020_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1590\/abd1806-4841.20164527","volume":"91","author":"AC Sala","year":"2016","unstructured":"Sala AC, Cunha PR, Pinto CA, Alves CA, Paiva IB, Araujo AP. Scleromyxedema: clinical diagnosis and autopsy findings. An Bras Dermatol. 2016;91(5 suppl 1):48\u201350.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"1020_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3949\/ccjm.50.2.189","volume":"50","author":"ML Muldrow","year":"1983","unstructured":"Muldrow ML, Bailin PL. Scleromyxedema associated with IgG lambda multiple myeloma. Cleve Clin Q. 1983 Summer;50(2):189\u201395.","journal-title":"Cleve Clin Q"},{"issue":"4","key":"1020_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2141.2012.09088.x","volume":"157","author":"CK Yeung","year":"2012","unstructured":"Yeung CK, Loong F, Kwong YL. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol. 2012;157(4):411.","journal-title":"Br J Haematol"},{"issue":"10","key":"1020_CR21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/rheumatology\/ker209","volume":"50","author":"R Bos","year":"2011","unstructured":"Bos R, de Waal EG, Kuiper H, Hazenberg BP, Vellenga E. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatol (Oxf). 2011;50(10):1925\u20136.","journal-title":"Rheumatol (Oxf)"},{"issue":"5","key":"1020_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1600-0609.2012.01772.x","volume":"88","author":"J Ca\u00f1ueto","year":"2012","unstructured":"Ca\u00f1ueto J, Labrador J, Rom\u00e1n C, Santos-Briz A, Contreras T, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed\/refractory scleromyxedema: A rare disease with new clinical insights. Eur J Haematol. 2012;88(5):450\u20134.","journal-title":"Eur J Haematol"},{"issue":"11","key":"1020_CR23","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.leukres.2011.07.021","volume":"35","author":"M Migkou","year":"2011","unstructured":"Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res. 2011;35(11):e209\u201311.","journal-title":"Leuk Res"},{"issue":"5","key":"1020_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4065\/79.5.687","volume":"79","author":"S Yaqub","year":"2004","unstructured":"Yaqub S, Moder KG, Lacy MQ. Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc. 2004;79(5):687\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1020_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1086\/679726","volume":"5","author":"WL Feyereisn","year":"2015","unstructured":"Feyereisn WL, Fenstad ER, McCully RB, Lacy MQ. Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature. Pulm Circ. 2015;5(1):211\u20136.","journal-title":"Pulm Circ"},{"issue":"4","key":"1020_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4103\/0019-5154.135538","volume":"59","author":"PA Rather","year":"2014","unstructured":"Rather PA, Hussain M, Bagdadi F. Localized cutaneous mucinosis associated with multiple myeloma: A rare presentation. Indian J Dermatol. 2014;59(4):422.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"1020_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-4362.1987.tb00530.x","volume":"26","author":"AP Truhan","year":"1987","unstructured":"Truhan AP, Roenigk HH Jr. Lichen myxedematosus. An unusual case with rapid progression and possible internal involvement. Int J Dermatol. 1987;26(2):91\u20135.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1020_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/0378-6323.13787","volume":"71","author":"CM Kuldeep","year":"2005","unstructured":"Kuldeep CM, Mittal AK, Gupta LK, Paliwal VK, Sharma P, Garg A. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol. 2005;71(1):44\u20135.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1020_CR29","first-page":"1071","volume":"137","author":"AM Feasel","year":"2001","unstructured":"Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001;137:1071.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1020_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00128071-200809040-00008","volume":"9","author":"S Ataergin","year":"2008","unstructured":"Ataergin S, Arpaci F, Demiriz M, Ozet A. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol. 2008;9(4):271\u20133.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1020_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0025-6196(11)65128-8","volume":"74","author":"D Rayson","year":"1999","unstructured":"Rayson D, Lust JA, Duncan A, Su WP. Scleromyxedema: A complete response to prednisone. Mayo Clin Proc. 1999 May;74(5):481\u20134.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1020_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archderm.1976.01630250027008","volume":"112","author":"RC Wright","year":"1976","unstructured":"Wright RC, Franco RS, Denton D, Blaney DJ. Scleromyxedema. Arch Dermatol. 1976 Jan;112(1):63\u20136.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1020_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1346-8138.2006.00047.x","volume":"33","author":"YC Lin","year":"2006","unstructured":"Lin YC, Wang HC, Shen JL. Scleromyxedema: an experience using treatment with systemic corticosteroid and review of the published work. J Dermatol. 2006 Mar;33(3):207\u201310.","journal-title":"J Dermatol"},{"issue":"4","key":"1020_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jaad.2005.04.012","volume":"53","author":"A Kreuter","year":"2005","unstructured":"Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol. 2005 Oct;53(4):739\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"2 Suppl","key":"1020_CR35","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.jaad.2004.03.023","volume":"51","author":"KB Horn","year":"2004","unstructured":"Horn KB, Horn MA, Swan J, Singhal S, Guitart J. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S120\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1020_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/archderm.141.10.1277","volume":"141","author":"MQ Lacy","year":"2005","unstructured":"Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol. 2005 Oct;141(10):1277\u201382.","journal-title":"Arch Dermatol"},{"key":"1020_CR37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1365-2133.1987.tb07499.x","volume":"117","author":"AW MacFarlane","year":"1987","unstructured":"MacFarlane AW, Davenport A, Verbov JL, Goldsmith HJ. Scleromyxoedema\u2014successful treatment with plasma exchange and immunosuppression. Br J Dermatol. 1987;117:653\u20137.","journal-title":"Br J Dermatol"},{"issue":"5 Pt 1","key":"1020_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0190-9622(08)81176-0","volume":"22","author":"CH Keong","year":"1990","unstructured":"Keong CH, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, Iino Y, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990 May;22(5 Pt 1):842\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1020_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/archderm.1976.01630250031009","volume":"112","author":"TG Hill","year":"1976","unstructured":"Hill TG, Crawford JN, Rogers CC. Successful management of lichen myxedematosus. Rep Case Arch Dermatol. 1976 Jan;112(1):67\u20139.","journal-title":"Rep Case Arch Dermatol"},{"issue":"3","key":"1020_CR40","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1046\/j.1365-2133.2001.04091.x","volume":"144","author":"R Morris-Jones","year":"2001","unstructured":"Morris-Jones R, Staughton RC, Walker M, Sheridan DJ, Rajappan K, Leonard J, et al. Lichen myxoedematosus with associated cardiac abnormalities. Br J Dermatol. 2001;144(3):594\u20136.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1020_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2340\/00015555-1299","volume":"92","author":"M Bidier","year":"2012","unstructured":"Bidier M, Zschoche C, Gholam P, Enk AH, Hadaschik EN. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol. 2012;92(4):408\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1020_CR42","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46(4):1855\u20136.","journal-title":"Eur Respir J"},{"issue":"2","key":"1020_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1378\/chest.103.2.642","volume":"103","author":"KS Marvin","year":"1993","unstructured":"Marvin KS, Spellberg RD. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest. 1993;103(2):642\u20134.","journal-title":"Chest"},{"issue":"3","key":"1020_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ajh.2830470320","volume":"47","author":"S Nand","year":"1994","unstructured":"Nand S, Orfei E. Pulmonary hypertension in polycythemia vera. Am J Hematol. 1994;47(3):242\u20134.","journal-title":"Am J Hematol"},{"issue":"2","key":"1020_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1378\/chest.112.2.551","volume":"112","author":"LJ Rossoff","year":"1997","unstructured":"Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8\/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest. 1997;112(2):551\u20133.","journal-title":"Chest"},{"issue":"2","key":"1020_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z","volume":"60","author":"G Garc\u00eda-Manero","year":"1999","unstructured":"Garc\u00eda-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol. 1999;60(2):130\u20135.","journal-title":"Am J Hematol"},{"issue":"3","key":"1020_CR47","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1378\/chest.120.3.801","volume":"120","author":"D Dingli","year":"2001","unstructured":"Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest. 2001;120(3):801\u20138.","journal-title":"Chest"},{"issue":"3","key":"1020_CR48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1046\/j.1365-2141.2002.03695.x","volume":"118","author":"DP Steensma","year":"2002","unstructured":"Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;118(3):813\u20136.","journal-title":"Br J Haematol"},{"issue":"6","key":"1020_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7326\/0003-4819-143-6-200509200-00017","volume":"143","author":"U Popat","year":"2005","unstructured":"Popat U, Frost A, Liu E, May R, Bag R, Reddy V, et al. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med. 2005;143(6):466\u20137.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1020_CR50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00277-006-0124-2","volume":"85","author":"C Rostagno","year":"2006","unstructured":"Rostagno C, Ciolli S. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma. Ann Hematol. 2006;85(9):627\u20138.","journal-title":"Ann Hematol"},{"issue":"3","key":"1020_CR51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/sj.leu.2404943","volume":"22","author":"A Cortelezzi","year":"2008","unstructured":"Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia. 2008;22(3):646\u20139.","journal-title":"Leukemia."},{"issue":"1","key":"1020_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1183\/09031936.00157707","volume":"33","author":"E Willems","year":"2009","unstructured":"Willems E, Canivet JL, Ghaye B, de Leval L, Radermecker M, et al. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J. 2009;33(1):213\u20136.","journal-title":"Eur Respir J"},{"issue":"137","key":"1020_CR53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1183\/16000617.0041-2015","volume":"24","author":"Y Adir","year":"2015","unstructured":"Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir Rev. 2015;24(137):400\u201310.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"1020_CR54","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1086\/682430","volume":"5","author":"U Krishnan","year":"2015","unstructured":"Krishnan U, Mark TM, Niesvizky R, Sobol I. Pulmonary hypertension complicating multiple myeloma. Pulm Circ. 2015;5(3):590\u20137.","journal-title":"Pulm Circ."},{"issue":"3","key":"1020_CR55","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.healun.2014.09.009","volume":"34","author":"EC Roach","year":"2015","unstructured":"Roach EC, Park MM, Tang WH, Thomas JD, Asosingh K, Kalaycio M, et al. Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. J Heart Lung Transplant. 2015;34(3):390\u20134.","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"1020_CR56","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00277-016-2765-0","volume":"95","author":"Mervat M. Mattar","year":"2016","unstructured":"Mattar MM, Morad MA, El Husseiny NM, Ali NH, El Demerdash DM. Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. Ann Hematol. 2016;95(10):1611\u20136.","journal-title":"Annals of Hematology"},{"issue":"5","key":"1020_CR57","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.05.00133904","volume":"26","author":"D Montani","year":"2005","unstructured":"Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, et al. Reversibility of pulmonary arterial hypertension in HIV\/HHV8-associated Castleman's disease. Eur Respir J. 2005 Nov;26(5):969\u201372.","journal-title":"Eur Respir J"},{"issue":"4_MeetingAbstra","key":"1020_CR58","doi-asserted-by":"publisher","first-page":"155A","DOI":"10.1378\/chest.1702447","volume":"144","author":"P Taytawat","year":"2013","unstructured":"Taytawat P. Reversible pulmonary hypertension and isolated right heart failure associated with multiple myeloma. Chest. 2013;144(4_MeetingAbstracts):155A.","journal-title":"Chest"},{"issue":"11","key":"1020_CR59","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2169\/internalmedicine.53.1672","volume":"53","author":"S Tamura","year":"2014","unstructured":"Tamura S, Koyama A, Shiotani C, Kurihara T, Nishikawa A, Okamoto Y, et al. Successful bortezomib\/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. Intern Med. 2014;53(11):1171\u20135.","journal-title":"Intern Med"},{"issue":"6","key":"1020_CR60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1600-0609.2012.01780.x","volume":"88","author":"R Warsame","year":"2012","unstructured":"Warsame R, Kohut IE, Dispenzieri A. Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. Eur J Haematol. 2012;88(6):549\u201350.","journal-title":"Eur J Haematol"},{"issue":"9\u201310","key":"1020_CR61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00508-010-1361-x","volume":"122","author":"Z Adam","year":"2010","unstructured":"Adam Z, Krej\u010d\u00ed M, Pour L, Feit J, B\u00fcchler T, H\u00e1jek R. IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen. Wien Klin Wochenschr. 2010;122(9\u201310):311\u20134.","journal-title":"Wien Klin Wochenschr"},{"key":"1020_CR62","doi-asserted-by":"crossref","unstructured":"Chinen K, Fujioka Y. Severe pulmonary hypertension caused by smoldering plasma cell myeloma: an autopsy case of POEMS syndrome. Case Rep Med. 2012:836893.","DOI":"10.1155\/2012\/836893"},{"issue":"4 Supp","key":"1020_CR63","doi-asserted-by":"publisher","first-page":"994A","DOI":"10.1378\/chest.2263218","volume":"148","author":"A Fox","year":"2015","unstructured":"Fox A, Farr G, Grinnan D. Improvement in pulmonary arterial hypertension associated with Castleman's disease after treatment with ambrisentan and rituximab. Chest. 2015 Oct;148(4 Supp):994A.","journal-title":"Chest"},{"issue":"9","key":"1020_CR64","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","volume":"107","author":"S Miyakoshi","year":"2006","unstructured":"Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492\u20134.","journal-title":"Blood"},{"issue":"3","key":"1020_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2006-03-011494","volume":"108","author":"JE Boyer","year":"2006","unstructured":"Boyer JE, Batra RB, Ascensao JL, Schechter GP. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood. 2006;108(3):1113.","journal-title":"Blood"},{"issue":"5","key":"1020_CR66","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1532\/IJH97.06142","volume":"84","author":"A Gotoh","year":"2006","unstructured":"Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, et al. Lung injury associated with bortezomib therapy in relapsed\/refractory multiple myeloma in Japan: a questionnaire-based report from the \"lung injury by Bortezomib\" joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol. 2006;84(5):406\u201312.","journal-title":"Int J Hematol"},{"issue":"6","key":"1020_CR67","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.mjt.0000245224.20913.0d","volume":"13","author":"A Ohri","year":"2006","unstructured":"Ohri A, Arena FP. Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther. 2006;13(6):553\u20135.","journal-title":"Am J Ther"},{"issue":"1","key":"1020_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10428190600988010","volume":"48","author":"E Chew","year":"2007","unstructured":"Chew E, Filshie R, Wei A. Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma. 2007;48(1):212\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1020_CR69","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.20891","volume":"82","author":"A Duek","year":"2007","unstructured":"Duek A, Feldberg E, Haran M, Berrebi A. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Am J Hematol. 2007;82(6):502\u20133.","journal-title":"Am J Hematol"},{"issue":"7","key":"1020_CR70","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.leukres.2006.09.015","volume":"31","author":"V Pitini","year":"2007","unstructured":"Pitini V, Arrigo C, Altavilla G, Naro C. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res. 2007;31(7):1027\u20138.","journal-title":"Leuk Res"},{"issue":"22","key":"1020_CR71","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1200\/JCO.2006.10.0164","volume":"25","author":"P Zappasodi","year":"2007","unstructured":"Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007;25(22):3380\u20131.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1020_CR72","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1093\/annonc\/mdn287","volume":"19","author":"C Lafaras","year":"2008","unstructured":"Lafaras C, Mandala E, Verrou E, Platogiannis D, Barbetakis N, et al. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol. 2008;19(10):1765\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"1020_CR73","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1097\/MJT.0b013e3181cea0ef","volume":"18","author":"A Ghose","year":"2011","unstructured":"Ghose A, Tariq Z, Taj A, Chaudhary R. Acute dyspnea from treatment of AL amyloidosis with bortezomib. Am J Ther. 2011;18(4):e123\u20135.","journal-title":"Am J Ther"},{"issue":"17","key":"1020_CR74","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circ. 2012;125(17):2128\u201337.","journal-title":"Circ"},{"issue":"3","key":"1020_CR75","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1097\/01.mjt.0000433941.91996.5f","volume":"22","author":"C Akosman","year":"2015","unstructured":"Akosman C, Ordu C, Eroglu E, Oyan B. Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature. Am J Ther. 2015;22(3):e88\u201392.","journal-title":"Am J Ther"},{"issue":"3","key":"1020_CR76","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3960\/jslrt.55.163","volume":"55","author":"Y Sugita","year":"2015","unstructured":"Sugita Y, Ohwada C, Nagao Y, Kawajiri C, Shimizu R, Togasaki E, et al. Early-onset severe diffuse alveolar hemorrhage after bortezomib administration suggestive of pulmonary involvement of myeloma cells. J Clin Exp Hematop. 2015;55(3):163\u20138.","journal-title":"J Clin Exp Hematop"},{"issue":"2","key":"1020_CR77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","volume":"185","author":"B Ranchoux","year":"2015","unstructured":"Ranchoux B, G\u00fcnther S, Quarck R, Chaumais MC, Dorfm\u00fcller P, Antigny F, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356\u201371.","journal-title":"Am J Pathol"},{"issue":"1","key":"1020_CR78","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1183\/09031936.00154210","volume":"38","author":"D Dumitrescu","year":"2011","unstructured":"Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011 Jul;38(1):218\u201320.","journal-title":"Eur Respir J"},{"key":"1020_CR79","doi-asserted-by":"crossref","unstructured":"Meka S, Otoupalova E, Patel V, Cichewiz A, Dalal B. Rituximab: Friend or foe for PAH? 2016 Oct;150(4 Supp):1215A.","DOI":"10.1016\/j.chest.2016.08.1324"},{"issue":"Suppl 1","key":"1020_CR80","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.2459\/JCM.0b013e3283621adf","volume":"16","author":"D Montrone","year":"2015","unstructured":"Montrone D, Correale M, Franzese MG, Ieva R, Di Biase M, Capalbo SF. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med (Hagerstown). 2015 Jan;16(Suppl 1):S65.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"2","key":"1020_CR81","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","volume":"192","author":"E Spiekerkoetter","year":"2015","unstructured":"Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, et al. Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015 Jul 15;192(2):254\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1020_CR82","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1172\/JCI65592","volume":"123","author":"E Spiekerkoetter","year":"2013","unstructured":"Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013 Aug;123(8):3600\u201313.","journal-title":"J Clin Invest"},{"issue":"10","key":"1020_CR83","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005 Oct;115(10):2811\u201321.","journal-title":"J Clin Invest"},{"issue":"8","key":"1020_CR84","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/ard.2004.029074","volume":"64","author":"Y Kamata","year":"2005","unstructured":"Kamata Y, Nara H, Sato H, Masuyama JI, Minota S, Yoshio T. Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension. Ann Rheum Dis. 2005 Aug;64(8):1236\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1020_CR85","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1183\/09031936.00185713","volume":"43","author":"L Harbaum","year":"2014","unstructured":"Harbaum L, Hennigs JK, Baumann HJ, Bokemeyer C, Olschewski H, Klose H. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy. Eur Respir J. 2014 May;43(5):1513\u20135.","journal-title":"Eur Respir J"},{"issue":"3","key":"1020_CR86","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/030097400750002120","volume":"29","author":"C Ferri","year":"2000","unstructured":"Ferri C, Emdin M, Storino FA, Giuggioli D, Longombardo G, Greco F, et al. Isolated pulmonary hypertension in diffuse cutaneous systemic sclerosis successfully treated with long-term plasma exchange. Scand J Rheumatol. 2000;29(3):198\u2013200.","journal-title":"Scand J Rheumatol"},{"key":"1020_CR87","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/978-3-662-45805-1_18","volume":"218","author":"J Meloche","year":"2013","unstructured":"Meloche J, Renard S, Provencher S, Bonnet S. Anti-inflammatory and immunosuppressive agents in PAH. Handb Exp Pharmacol. 2013;218:437\u201376.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1020_CR88","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1164\/ajrccm.183.1.139","volume":"183","author":"A Ogawa","year":"2011","unstructured":"Ogawa A, Nakamura K, Mizoguchi H, Fujii N, Fujio H, Kusano KF, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011 Jan 1;183(1):139\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1020_CR89","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/thx.54.4.372","volume":"54","author":"F Bellotto","year":"1999","unstructured":"Bellotto F, Chiavacci P, Laveder F, Angelini A, Thiene G, Marcolongo R. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax. 1999 Apr;54(4):372\u20134.","journal-title":"Thorax"},{"issue":"7","key":"1020_CR90","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1017\/S1047951117000464","volume":"27","author":"M Aggarwal","year":"2017","unstructured":"Aggarwal M. Grady RM1. Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication. Cardiol Young. 2017 Sep;27(7):1410\u20132.","journal-title":"Cardiol Young"},{"key":"1020_CR91","unstructured":"Haritha J, Syed H, Nandan A, Grinnan D. Report shows rituximab may help treat MCTD-associated PAH. Rheumatologist. 2018 April 26."},{"issue":"8","key":"1020_CR92","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/0961203307087610","volume":"17","author":"S Hennigan","year":"2008","unstructured":"Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus. 2008 Aug;17(8):754\u20136.","journal-title":"Lupus"},{"issue":"4","key":"1020_CR93","first-page":"657","volume":"31","author":"J Padilla-Ibarra","year":"2013","unstructured":"Padilla-Ibarra J, Sanchez-Ortiz A, Sandoval-Castro C, Ramos-Remus C. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. Clin Exp Rheumatol. 2013 Jul-Aug;31(4):657\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1020_CR94","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.atherosclerosissup.2012.10.029","volume":"14","author":"M Dandel","year":"2013","unstructured":"Dandel M, Wallukat G, Englert A, Hetzer R. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension. Atheroscler Suppl. 2013 Jan;14(1):203\u201311.","journal-title":"Atheroscler Suppl"},{"issue":"3","key":"1020_CR95","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000478744","volume":"94","author":"C Nagel","year":"2017","unstructured":"Nagel C, Ewert R, Egenlauf B, Lehmkuhl HB, Rosenkranz S, Benjamin N, et al. Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with severe idiopathic pulmonary arterial hypertension. Respir. 2017;94(3):263\u201371.","journal-title":"Respir"},{"issue":"5","key":"1020_CR96","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s11033-010-0390-x","volume":"38","author":"W Wang","year":"2011","unstructured":"Wang W, Wang YL, Chen XY, Li YT, Hao W, Jin YP, et al. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep. 2011 Jun;38(5):3277\u201384.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"1020_CR97","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1183\/09031936.00028310","volume":"37","author":"LC Price","year":"2011","unstructured":"Price LC, Montani D, Tcherakian C, Dorfm\u00fcller P, Souza R, Gambaryan N, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J. 2011 Apr;37(4):813\u201322.","journal-title":"Eur Respir J"},{"issue":"5","key":"1020_CR98","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1165\/rcmb.2011-0331OC","volume":"47","author":"SY Kim","year":"2012","unstructured":"Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, et al. Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2012;47(5):698\u2013708.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"1020_CR99","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10238-013-0244-7","volume":"14","author":"YY Wang","year":"2014","unstructured":"Wang YY, Luan Y, Zhang X, Lin M, Zhang ZH, et al. Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension. Clin Exp Med. 2014;14(3):321\u20139.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1020_CR100","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/ijmm.2013.1562","volume":"33","author":"X Zhang","year":"2014","unstructured":"Zhang X, Wang ZS, Luan Y, Lin M, Zhu XB, Ma Y, et al. The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension. Int J Mol Med. 2014;33(1):105\u201310.","journal-title":"Int J Mol Med"},{"issue":"3","key":"1020_CR101","doi-asserted-by":"publisher","first-page":"C482","DOI":"10.1152\/ajpcell.00324.2015","volume":"311","author":"Jun Zhang","year":"2016","unstructured":"Zhang J, Lu W, Chen Y, Jiang Q, Yang K1, Li M, et al. Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs. Am J Physiol Cell Physiol 2016;311(3):C482\u2013C497.","journal-title":"American Journal of Physiology-Cell Physiology"},{"key":"1020_CR102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lfs.2017.02.007","volume":"173","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Wu Y, Shi W, Wang J, Yan X, Wang Q, et al. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling. Life Sci. 2017;173:36\u201342.","journal-title":"Life Sci"},{"issue":"1","key":"1020_CR103","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000520","volume":"3","author":"YF Ibrahim","year":"2014","unstructured":"Ibrahim YF, Wong CM, Pavlickova L, Liu L, Trasar L, et al. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing. J Am Heart Assoc. 2014;3(1):e000520.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1020_CR104","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/archderm.139.6.815","volume":"139","author":"F Rongioletti","year":"2003","unstructured":"Rongioletti F, Cattarini G, Sottofattori E, Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol. 2003 Jun;139(6):815\u20136.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1020_CR105","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1378\/chest.11-0793","volume":"141","author":"LC Price","year":"2012","unstructured":"Price LC, Wort SJ, Perros F, Dorfm\u00fcller P, Huertas A, Montani D, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012 Jan;141(1):210\u201321.","journal-title":"Chest."},{"issue":"5","key":"1020_CR106","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/01.CIR.0000156326.48823.55","volume":"111","author":"JX Yuan","year":"2005","unstructured":"Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circ. 2005 Feb 8;111(5):534\u20138.","journal-title":"Circ"},{"issue":"2","key":"1020_CR107","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/2045893217701438","volume":"7","author":"O Boucherat","year":"2017","unstructured":"Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm Circ. 2017 Apr-Jun;7(2):285\u201399.","journal-title":"Pulm Circ"},{"issue":"9","key":"1020_CR108","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/thx.2004.029082","volume":"60","author":"MC Tamby","year":"2005","unstructured":"Tamby MC, Chanseaud Y, Humbert M, Fermanian J, Guilpain P, Garcia-de-la-Pe\u00f1a-Lefebvre P, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005 Sep;60(9):765\u201372.","journal-title":"Thorax"},{"issue":"4","key":"1020_CR109","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.06.00152705","volume":"28","author":"MC Tamby","year":"2006","unstructured":"Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J. 2006 Oct;28(4):799\u2013807.","journal-title":"Eur Respir J"},{"issue":"130","key":"1020_CR110","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1183\/09059180.00007513","volume":"22","author":"C Guignabert","year":"2013","unstructured":"Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev. 2013 Dec;22(130):543\u201351.","journal-title":"Eur Respir Rev"},{"issue":"3","key":"1020_CR111","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","volume":"186","author":"E Stacher","year":"2012","unstructured":"Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012 Aug 1;186(3):261\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1020_CR112","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2169\/internalmedicine.41.109","volume":"41","author":"N Kawamura","year":"2002","unstructured":"Kawamura N, Tsutsui H, Fukuyama K, Hayashidani S, Koike G, Egashira K, et al. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity. Intern Med. 2002 Feb;41(2):109\u201312.","journal-title":"Intern Med"},{"issue":"11","key":"1020_CR113","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","volume":"62","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003 Nov;62(11):1088\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1020_CR114","first-page":"396","volume":"85","author":"JE Bordley","year":"1949","unstructured":"Bordley JE, Carey RA, et al. Preliminary observations on the effect of adrenocorticotropic hormone in allergic diseases. Bull Johns Hopkins Hosp. 1949 Nov;85(5):396\u20138.","journal-title":"Bull Johns Hopkins Hosp"},{"issue":"9983","key":"1020_CR115","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015 May 30;385(9983):2197\u2013208.","journal-title":"Lancet"},{"issue":"2","key":"1020_CR116","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010 Apr;47(2):115\u201323.","journal-title":"Semin Hematol"},{"issue":"5","key":"1020_CR117","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 5;116(5):679\u201386.","journal-title":"Blood"},{"issue":"6","key":"1020_CR118","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.18632\/oncotarget.6658","volume":"7","author":"S Lub","year":"2016","unstructured":"Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget. 2016;7(6):6521\u201337.","journal-title":"Oncotarget"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-1020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-1020-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-1020-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:22:09Z","timestamp":1610065329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-1020-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-1020-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this manuscript meets the definition of a case report, Institutional Review Board (IRB) review was not required for publication; the Marshfield Clinic Health System\u2019s IRB does not require written patient consent unless identifiable information (i.e., facial photographs) is published. Care was provided in accordance with standard-of-care procedures and best-practice recommendations at the health care system. Convenience.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that we have obtained verbal consent to publish from the patient\/participant to report the individual patient\u2019s data and medical images. Verbal consent was obtained from the patient. We have also now obtained written informed consent from the wife of the patient, after he passed away.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}